Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C18H17Br2N2O5 |
Molar mass | 501.151 g·mol−1 |
3D model ( JSmol) | |
| |
|
Eprotirome is a thyromimetic drug that has been investigated for the treatment of dyslipidemia. A Phase III trial in humans was discontinued after the drug was found to have negative effects on cartilage in dogs. [1] [2]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C18H17Br2N2O5 |
Molar mass | 501.151 g·mol−1 |
3D model ( JSmol) | |
| |
|
Eprotirome is a thyromimetic drug that has been investigated for the treatment of dyslipidemia. A Phase III trial in humans was discontinued after the drug was found to have negative effects on cartilage in dogs. [1] [2]